Unlike malignancies such as GIST, breast cancer, or melanoma—where driver mutations are routinely targeted—HCC lacks approved therapies for its most frequent mutations, including TERT, CTNNB1, and TP53. This evidence concerns the gene TERT and hepatocellular carcinoma.